Characteristics and Safety Profile in Patient Received Ixazomib in China: Interim Analysis of a National, Prospective, Non-Interventional Study of Using Ixazomib in Real-World Clinical Practice (INFINITE Study)

被引：0
|
作者：
Fu, Chengcheng [1 ,2 ]
Zhou, Xin [3 ]
Zhuang, Junling [4 ]
Zhou, Fan [5 ]
Li, Yuhua [6 ]
Chen, Wenming [7 ]
Fu, Rong [8 ]
Fang, Baijun [9 ]
Niu, Ting [10 ]
Zhang, Hao [11 ]
Li, Lin [12 ]
Wu, Depei [1 ,2 ]
机构：
[1] Soochow Univ, Natl Clin Res Ctr Hematol Dis, Jiangsu Inst Hematol, Affiliated Hosp 1, Suzhou, Peoples R China
[2] Soochow Univ, Collaborat Innovat Ctr Hematol, Suzhou, Peoples R China
[3] Nanjing Med Univ, Dept Hematol, Wuxi Peoples Hosp, Wuxi, Jiangsu, Peoples R China
[4] Peking Union Med Coll Hosp, Dept Hematol, Beijing, Peoples R China
[5] Shanghai Jingan Dist Zhabei Cent Hosp, Dept Hematol, Shanghai, Peoples R China
[6] Southern Med Univ, Dept Hematol, Zhujiang Hosp, Guangzhou, Peoples R China
[7] Capital Med Univ, Beijing Chao Yang Hosp, Dept Hematol, Beijing, Peoples R China
[8] Tianjin Med Univ, Dept Hematol, Gen Hosp, Tianjin, Peoples R China
[9] Henan Canc Hosp, Dept Hematol, Zhengzhou, Peoples R China
[10] Sichuan Univ, West China Hosp, Dept Hematol, Chengdu, Peoples R China
[11] Jining Med Coll, Affiliated Hosp, Jining, Peoples R China
[12] Takeda China Int Trading Co Ltd, Shanghai, Peoples R China
来源：
BLOOD | 2022年 / 140卷
关键词：
D O I：
10.1182/blood-2022-165127
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
653
引用
收藏
页码：12642 / 12644
页数：3
相关论文
共 50 条
  • [41] The Efficacy and Safety Profile of Ixazomib-Based Regimens in Patients with Relapsed/Refractory Multiple Myeloma in Routine Clinical Practice: Real World Data from a Multi-Center Study in China
    Li, Jing
    Bao, Li
    Xia, Zhong-jun
    Ding, Kaiyang
    Li, Bingzong
    Chen, Bing
    Fu, Zhengzheng
    Wang, Sili
    Zhang, Wenhao
    Zhou, Xin
    Hua, Luoming
    Yang, Wei
    Jun, Luo
    Wang, Liang
    Xu, Tianhong
    Yang, Yang
    Wang, Weida
    Wu, Guolin
    Huang, Yun
    Liu, Peng
    BLOOD, 2019, 134
  • [42] Real-world non-interventional long-term post-authorisation safety study of ruxolitinib in myelofibrosis
    Barraco, Fiorenza
    Grei, Richard
    Herbrecht, Raoul
    Schmidt, Burkhard
    Reiter, Andreas
    Willenbacher, Wolfgang
    Raymakers, Reinier
    Liersch, Rudiger
    Wroclawska, Monika
    Pack, Robert
    Burock, Karin
    Karumanchi, Divyadeep
    Gisslinger, Heinz
    BRITISH JOURNAL OF HAEMATOLOGY, 2020, 191 (05) : 764 - 774
  • [43] A multicentre, prospective, non-interventional study evaluating the safety of dapagliflozin in patients with type 2 diabetes in routine clinical practice in China (DONATE)
    Lixin Guo
    Jing Wang
    Li Li
    Lin Yuan
    Sheng Chen
    Hui Wang
    Tonghuan Li
    Lin Qi
    Hong Yang
    BMC Medicine, 21
  • [44] A multicentre, prospective, non-interventional study evaluating the safety of dapagliflozin in patients with type 2 diabetes in routine clinical practice in China (DONATE)
    Guo, Lixin
    Wang, Jing
    Li, Li
    Yuan, Lin
    Chen, Sheng
    Wang, Hui
    Li, Tonghuan
    Qi, Lin
    Yang, Hong
    BMC MEDICINE, 2023, 21 (01)
  • [45] PROVE: Retrospective, non-interventional, Phase IV study of perampanel in real-world clinical care of patients with epilepsy
    Wechsler, Robert T.
    Wheless, James
    Zafar, Muhammad
    Huesmann, Graham R.
    Lancman, Marcelo
    Segal, Eric
    Chez, Michael
    Aboumatar, Sami
    Patten, Anna
    Salah, Alejandro
    Malhotra, Manoj
    EPILEPSIA OPEN, 2022, 7 (02) : 293 - 305
  • [46] Baseline characteristics and clinical features of patients with heart failure with reduced ejection fraction: a European real-world, non-interventional registry study
    Zeymer, U.
    Lunde, L. H.
    Barrios, V
    Fonseca, C.
    Clark, A. L.
    Damy, T.
    Drozdz, J.
    Kalus, S.
    Koch, C.
    Maggioni, A.
    EUROPEAN HEART JOURNAL, 2020, 41 : 1063 - 1063
  • [47] 4 Years Safety of Fingolimod in Real World: PANGAEA a Non-Interventional Study of Safety, Effectiveness and Pharmacoeconomic is Data for Fingolimod Patients in Daily Clinical Practice
    Ziemssen, Tjalf
    Albrecht, Holger
    Haas, Judith
    Klotz, Luisa
    Lang, Michael
    Lassek, Chrstoph
    Schmidt, Stephan
    Tackenberg, Bjorn
    Cornelissen, Christian
    NEUROLOGY, 2016, 86
  • [48] 4 years safety of fingolimod in real world: PANGAEA, a non-interventional study of safety, effectiveness and pharmacoeconomic data for fingolimod patients in daily clinical practice
    Ziemssen, T.
    Albrecht, H.
    Haas, J.
    Klotz, L.
    Lang, M.
    Lassek, C.
    Schmidt, S.
    Tackenberg, B.
    Cornelissen, C.
    EUROPEAN JOURNAL OF NEUROLOGY, 2016, 23 : 416 - 416
  • [49] Real-World Treatment Patterns in Chinese Stage III NSCLC Patients - A Prospective, Non-Interventional Study (MOOREA trial)
    Yu, J.
    Xing, L.
    Cheng, G.
    Chen, L.
    Dong, L.
    Fu, X.
    Guo, Y.
    Han, Z.
    Jiang, D.
    Li, J.
    Lin, Y.
    Liu, A.
    Liu, J.
    Liu, J.
    Liu, Y.
    Lv, D.
    Ma, C.
    Ren, Y.
    Wang, S.
    Wang, Y.
    Xiao, C.
    Yan, S.
    Yang, F.
    Yang, W.
    Zang, A.
    Zhang, X.
    Zhang, Y.
    Zhao, R.
    Zhou, J.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S367 - S368
  • [50] A multicenter, prospective, non-interventional real-world study to assess the effectiveness of mecapegfilgrastim in preventing neutropenia in patients with gastrointestinal cancer
    Mao, Chenyu
    He, Ye
    Xu, Nong
    Yan, Haijiao
    Zhang, Ningling
    Cheng, Gang
    Jiang, Hua
    Chen, Minbin
    Chen, Yong
    Wang, Xiaoguang
    Gu, Yulan
    Shen, Peng
    Zhang, Guifang
    Yan, Jun
    Yang, Zhe
    Ding, Lifang
    Han, Zhengxiang
    Wang, Zhanggui
    Zhang, Junqi
    Zheng, Weie
    Wang, Jufeng
    Qin, Shukui
    IMMUNITY INFLAMMATION AND DISEASE, 2024, 12 (08)
12345